Bristol-Myers Squibb Company (BMY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Core Insights - The ADEPT-2 study will continue with the enrollment of additional patients following the identification of irregularities during clinical trial site reviews [1] - The company reported the irregularities to the data monitoring committee and the FDA, leading to the exclusion of certain sites and patients from the study [1] - An agreement was reached with the FDA and the DMC to conduct an interim analysis of the study [2]